The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan-Reference-Cited by-同舟云学术

The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan

Published:2011-05-07 Issue:7 Volume:46 Page:944-952
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Oze Tsugiko,Hiramatsu Naoki,Yakushijin Takayuki,Mochizuki Kiyoshi,Imanaka Kazuho,Yamada Akira,Oshita Masahide,Kaneko Akira,Hagiwara Hideki,Mita Eiji,Ito Toshifumi,Nagase Toshihiko,Inui Yoshiaki,Hijioka Taizo,Tamura Shinji,Yoshihara Harumasa,Hayashi Eijiro,Imai Yasuharu,Kato Michio,Hosui Atsushi,Miyagi Takuya,Yoshida Yuichi,Ishida Hisashi,Tatsumi Tomohide,Kiso Shinichi,Kanto Tatsuya,Kasahara Akinori,Takehara Tetsuo,Hayashi Norio

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-011-0403-0.pdf

Reference29 articles.

1. Poynarl T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.

2. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671–5.

3. Hiramatsu N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Haruna Y, et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol. 1995;22:135–42.

4. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998;27:1394–402.

5. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174–81.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection;Annals of Hepatology;2022-01

2. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct‐acting antiviral agents in chronic hepatitis C virus‐infected patients;Journal of Gastroenterology and Hepatology;2020-10-11

3. Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C;PLOS ONE;2016-03-22

4. Comparison of Acoustic Structure Quantification (ASQ), shearwave elastography and histology in patients with diffuse hepatopathies;BMC Medical Imaging;2015-12

5. Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin;Hepatology International;2015-08-12